SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Recruiting · NCT05345327 · Registry updated 2024-12-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2024-12-20 | NCT05345327 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Monash University | 75 |
| The George Institute | 22 |
| The University of New South Wales | 23 |
| University of Sydney | 73 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jaffna Teaching Hospital | Jaffna | Sri Lanka | 2 |
| Kandy National Hospital | Kandy | Sri Lanka | 3 |
| Monash University | Melbourne | Australia | 4 |
| National Hospital - Galle | Galle | Sri Lanka | 1 |
| National Hospital of Sri Lanka 1 | Colombo | Sri Lanka | 1 |
| National Hospital of Sri Lanka 2 | Colombo | Sri Lanka | 1 |
| The George Institute for Global Health | Brisbane | Australia | 1 |
| The George Institute for Global Health | Sydney | Australia | 1 |